Pharmacokinetic and Safety Study of Bismuth Potassium Citrate Formulations in Healthy Subjects [0.03%]
枸橼酸铋钾制剂在健康受试者中的药代动力学和安全性研究
Hong-Yu Luo,Shuo-Guo Xu,Li-Chen Gao et al.
Hong-Yu Luo et al.
Background: Potassium bismuth citrate is a gastric mucosal protector and a key drug for treating peptic ulcers. Objective: To evaluate ...
Real-World Experience of Carglumic Acid for Methylmalonic and Propionic Acidurias: An Interim Analysis of the Multicentre Observational PROTECT Study [0.03%]
甲基马尿酸和丙酸血症患者使用Carglumic酸进行治疗的真实世界经验：多中心观察PROTECT研究的中期分析
Sufin Yap,Delphine Lamireau,Francois Feillet et al.
Sufin Yap et al.
Background and objective: Methylmalonic aciduria (MMA) and propionic aciduria (PA) are organic acidurias characterised by the accumulation of toxic metabolites and hyperammonaemia related to secondary N-acetylglutamate de...
Observational Study
Drugs in R&D. 2024 Mar;24(1):69-80. DOI:10.1007/s40268-023-00449-z 2024
Drug-Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism [0.03%]
涉及CYP3A4和CYP2D6介导代谢的右美他佐辛（REL-1017）的药物相互作用研究
Nicola Ferri,Sara De Martin,James Stuart et al.
Nicola Ferri et al.
Background and objective: Esmethadone (dextromethadone; d-methadone; S-methadone (+)-methadone; REL-1017) is the opioid inactive dextro-isomer of racemic methadone. Esmethadone is a low potency N-methyl-D-aspartate (NMDA)...
Unveiling the Influence of a High-Fat Meal on the Pharmacokinetics of Oral Globalagliatin, A Glucokinase Activator, in Healthy Chinese Volunteers [0.03%]
高脂饮食对口服降糖药格列沙今药代动力学影响的首次人体研究
Maodi Xu,Yaqin Wang,Xiaohu Wang et al.
Maodi Xu et al.
Introduction: Glucokinase (GK) plays a pivotal role in maintaining glucose homeostasis; globalagliatin, a newly developed drug, is a GK activator (GKA). This study constitutes a randomized, open-label, two-cycle, two-cros...
Efficacy and Safety of Methylphenidate and Atomoxetine in Medication-Naive Children with Attention-Deficit Hyperactivity Disorder in a Real-World Setting [0.03%]
注意缺陷多动障碍儿童使用哌甲酯和托莫西禁首次用药的疗效及安全性研究
Ying Zhang,Li Yin,Cun You et al.
Ying Zhang et al.
Background and objective: Methylphenidate (MPH) and atomoxetine (ATX) are the most common medications used to treat attention-deficit hyperactivity disorder (ADHD) in China; however, despite this, there is still a paucity...
A Guide to Expanding the Use of Buprenorphine Beyond Standard Initiations for Opioid Use Disorder [0.03%]
扩大纳洛酮用于治疗阿片类物质使用障碍的常规启动剂量之外的应用指南
James C Miller,Michael A Brooks,Kelly E Wurzel et al.
James C Miller et al.
Buprenorphine has become an important medication in the context of the ongoing opioid epidemic. However, complex pharmacologic properties and varying government regulations create barriers to its use. This narrative review is intended to fa...
Effect of High-Fat Food on the Pharmacokinetic Profile and Safety of SAF-189s, an ALK/ROS1 Inhibitor, in Healthy Chinese Adults [0.03%]
高脂饮食对中国健康受试者中ALK/ROS1抑制剂SAF-189药代动力学特征及安全性的影响
Huiling Qin,Yan Tan,Lei Diao et al.
Huiling Qin et al.
Background and objectives: This study was conducted to investigate the effect of high-fat meals on the pharmacokinetics (PK) and safety profile of SAF-189s, a novel ALK/ROS1 inhibitor. ...
Clinical Trial
Drugs in R&D. 2023 Dec;23(4):465-473. DOI:10.1007/s40268-023-00446-2 2023
Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC42, a Novel Farnesoid X Receptor Agonist [0.03%]
ASC42 I期临床研究：一种新型法尼醇X受体激动剂的安全性、耐受性、药代动力学及药效学研究
Handan He,Jinzi J Wu
Handan He
Background: ASC42 is a non-steroidal farnesoid X receptor agonist currently in clinical development for chronic liver diseases, such as nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) and primar...
Simvastatin Preferentially Targets FLT3/ITD Acute Myeloid Leukemia by Inhibiting MEK/ERK and p38-MAPK Signaling Pathways [0.03%]
辛伐他汀通过抑制MEK/ERK和p38-MAPK信号通路选择性地靶向FLT3/ITD急性髓系白血病
Genhong Li,Jingwei Yao,Zhen Lu et al.
Genhong Li et al.
Background: The FLT3/ITD mutation exists in many acute myeloid leukemia (AML) patients and is related to the poor prognosis of patients. In this study, we attempted to evaluate the antitumor activity of simvastatin, a mem...
Analytical and Functional Similarity of the Biosimilar Candidate ABP 654 to Ustekinumab Reference Product [0.03%]
ABP 654生物类似药候选者与ustekinumab参考药品的分析和功能相似性研究
Greg Cantin,Qian Liu,Bhavana Shah et al.
Greg Cantin et al.
Background and objective: ABP 654 is a proposed biosimilar to ustekinumab reference product (RP), a human immunoglobulin isotype class G subclass 1 kappa monoclonal antibody that acts as an antagonist of interleukin (IL)-...